The genetic test OFTA concerns only the genetic risk. For the global clinical risk assessment the integration of genetic data with behavioral data and medical history of the subject are required.

The test is not a diagnostic test. The test analyzes only the genetic variants associated with macular degeneration (AMD) scientifically relevant until today. Having a genetic predisposition to AMD does not mean that you will develop the disease. In addition a low genetic risk does not guarantee that you cannot be affected by AMD.

Macular degeneration (Age-related Macular Degeneration, AMD) is a degenerative multifactorial disease that affects the macula, which is the central part of the retina that allows for distinct vision and color vision.

The frequency of macular degeneration is higher in older people: it is estimated that after 85 years of age 13% of the population is affected by AMD. Every year, in Italy, 20,000 new cases are diagnosed.

If left untreated, age-related macular degeneration can lead to blindness, therefore early detection is critical. In recent years it was discovered that certain genetic variations may significantly increase the chances of contracting the disease: among these the most significant are due to the CFH gene (which plays an important role in the immune system) and to the ARMS2 gene (activated in the retina) . It is possible to prevent the disease eating in a healthy way , avoiding smoking and controlling weight, blood pressure and cholesterol.

Regular ophtalmologic consultations are the key for the early detection of the disease, particularly for people genetically predisposed,who can in this way significantly reduce their chances of getting sick by consuming adequate amounts of antioxidants, zinc and omega-3 fatty acids. Supplementation with antioxidants and minerals is also recommended for those who are already suffering from macular degeneration at an advanced stage.

Below the analyzed genes